Retrouvey Helene, Solaja Ogi, Baltzer Heather L
From the Division of Plastic and Reconstructive Surgery, University of Toronto.
Division of Plastic and Reconstructive Surgery, McMaster University, Toronto, Ontario, Canada.
Ann Plast Surg. 2019 Nov;83(5):542-547. doi: 10.1097/SAP.0000000000001848.
The use of intravenous heparin after digit replantation or revascularization (DRR) varies greatly. The insufficient evidence presents a lack of clinical equipoise needed for a randomized trial; as such, a matched propensity score analysis was performed to evaluate the role of postoperative anticoagulation after DRR. The purpose of this study was to determine if the use of postoperative therapeutic anticoagulation reduced the risk of digit failure.
A retrospective cohort of patients who underwent DRR from 2005 to 2016 was identified. A propensity score was calculated based on age, smoking, injury mechanism, procedure type, vein graft, and number of digits injured. Patients were matched 1:2 by propensity score to create 2 groups with similar risks of receiving anticoagulation postoperatively. Generalized estimating equation logistic model was used to determine differences in digit failure between groups.
Digit replantation or revascularization was performed on 282 patients (92% male; median age, 43 years). Postoperative anticoagulation was administered in 69 (24%) patients, with continuous IV heparin in 34 patients and intravenous heparin with dextran in 35 patients. Digit failure occurred in 88 patients overall, representing 38% of patients receiving anticoagulation and 29% of those not. Major complications were higher among the anticoagulated patients (13% vs 3.3%). After propensity score matching, use of anticoagulation was not associated with digit failure (odds ratio, 0.79; 95% confidence interval, 0.47-1.32).
Among DRR patients with similar predisposing characteristics for postoperative therapeutic heparin or dextran, the use of therapeutic anticoagulation does not have a protective effect against digit failure. Studies are needed to define the role of postoperative IV anticoagulation in DRR and to justify the risk of its administration.
手指再植或血管重建术后静脉使用肝素的情况差异很大。证据不足表明缺乏进行随机试验所需的临床平衡;因此,进行了匹配倾向评分分析以评估手指再植或血管重建术后抗凝治疗的作用。本研究的目的是确定术后进行治疗性抗凝是否能降低手指坏死的风险。
确定了一组2005年至2016年接受手指再植或血管重建的回顾性队列患者。根据年龄、吸烟情况、损伤机制、手术类型、静脉移植和受伤手指数量计算倾向评分。患者按倾向评分1:2匹配,以创建两组术后接受抗凝治疗风险相似的患者。使用广义估计方程逻辑模型确定两组之间手指坏死的差异。
对282例患者进行了手指再植或血管重建(92%为男性;中位年龄43岁)。69例(24%)患者接受了术后抗凝治疗,其中34例患者持续静脉注射肝素,35例患者静脉注射肝素加右旋糖酐。总体上有88例患者出现手指坏死,占接受抗凝治疗患者的38%,未接受抗凝治疗患者的29%。抗凝治疗患者的主要并发症发生率更高(13%对3.3%)。倾向评分匹配后,使用抗凝治疗与手指坏死无关(比值比,0.79;95%置信区间,0.47 - 1.32)。
在术后接受肝素或右旋糖酐治疗的倾向特征相似的手指再植或血管重建患者中,使用治疗性抗凝对预防手指坏死没有保护作用。需要开展研究来明确术后静脉抗凝在手指再植或血管重建中的作用,并证明其用药风险的合理性。